Leerink Swann Downgrades Kindred Biosciences To Market Perform

by Monica Gerson, Benzinga Staff Writer

December 4, 2014 8:43 AM | 12 seconds read | Make a Comment

Analysts at Leerink Swann downgraded Kindred Biosciences

KIN

from Outperform to Market Perform. The price target for Kindred Biosciences has been lowered from $11.25 to $6. Kindred Biosciences' shares fell 0.22% to close at $9.24 yesterday.

Market News and Data brought to you by Benzinga APIs

Posted In: Downgrades Analyst Ratings Leerink Swann

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Leerink Swann Downgrades Kindred Biosciences To Market Perform